Ixico Share Discussion Threads

[geoff80] 01/12/2016 09:59

More elderly people and dementia. IXI is an inevitable growth stock.

[geoff80] 01/12/2016 09:06

More elderly people and dementia. IXI is an inevitable growth stock.

[aishah] 25/11/2016 14:57

IXICO at the forefront of a medical and technical revolution

r o activeinvestors.co.uk/companies/news/169331/ixico-at-the-forefront-of-a-medical-and-technical-revolution-169331.html

[zlotini] 23/11/2016 19:54

Thanks for the posts AISHAH. The Proactive article makes for interesting reading and reinforces my expectation that Ixico has an exciting future. The interview with Hill is certainly worth viewing. How profitable it will be remains to be seen.

[aishah] 23/11/2016 09:42

IXICO Plc chief hugely excited by 'really big growth opportunities'

IXICO chief executive Derek Hill caught up with Proactive to discuss the company's full year results and new partnerships.

Hill tells Proactive: We're very focused on the brain. Neurodegenerative diseases have been our longer term focus - the perhaps best known one of those - Alzheimer's Disease which is the main cause of dementia.''

''Traditionally IXICO has, for the last 12 years, been working with pharmaceutical companies supporting them in developing drugs, particularly for neurodegenerative diseases ... but recently we've also got some of our technology crossing over from the world of developing drugs into being used alongside drugs in the clinics''.

''We're using technology that we have for many years been applying to support pharmaceutical companies developing drugs. We're now using that to help make those drugs safer when used with patients in the clinic once they're marketed'', Hill added.

Hill went on to say: ''We are involved in several European projects which are collaborations with the pharmaceutical industry but also with major academic centres across Europe'''.

[...]

[aishah] 22/11/2016 09:42

SMALL CAP IDEAS: Brain scanning expert IXICO makes money from monitoring the effects of drugs

The pharma industry is facing a challenge caused by shrinking healthcare budgets and a growing ageing population that means cost-benefit analysis increasingly provides the benchmarking for those who pay for our prescription drugs.
It means in the not too distant future that giant pharma companies will be paid on results, or what’s known in the jargon as patient outcomes.
Actually, it’s not just simple health economics as practised here in the UK by NICE (The National Institute for Health and Care Excellence) that’s the motive force driving through change.
It’s the realisation that a one-size-fits-all approach to healing the ill or treating the elderly just does not work.
Clever products: IXICO is an expert in brain scanning. It makes its money monitoring the effects of drugs on behalf of the companies developing them

IXICO is an expert in brain scanning. It makes its money monitoring the effects of drugs on behalf of the companies developing them
Because the genetic make-up of every human is subtly different, so we all react in different ways to the medication we are plied with.
With certain people the pills will work; with others they just don’t, or worse, the side-effects make them sicker.
But how do we tell just who will be susceptible to the latest cancer or MS drug and who will not?
The answer is both simple and quite complicated.
The simple answer is companion products, using the best of digital and medical technology, will be brought in to provide the answers.

The problem is that businesses such as Apple, which revolutionised the music industry, Google, Amazon or IBM, just don’t have the expertise required to enact the revolution.
The obstacle is not one of processing power or having the coders to pack a huge amount of medical knowledge into a series of algorithms.
No, the stumbling block is how the latest innovations are deployed within a heavily regulated framework.
And it is this that has kept the big boys out of the frame thus far, according to Derek Hill, chief executive and founder of IXICO.
'Companies are trying to get into the space but they are bit nervous of the regulated environment, that’s why there are opportunities for companies like us,' he said.
IXICO is an expert in brain scanning. It makes its money monitoring the effects of drugs on behalf of the companies developing them.
In the year ended September it generated around £3million in revenues from this source, which makes it a rarity among the minnows of the healthcare and technology sectors in that it is paid for its services.
In fact, it is being paid while it is developing products and it is working with the companies it reckons will be the early adopters of its technology – big pharmaceutical companies.
In September it made a breakthrough that reflects the way the landscape is changing within the industry, but also points in the direction the IXICO business is heading.
It landed a deal with the American giant Biogen to provide the brain scanning expertise that will allow physicians to monitor the effects of the company’s flagship product, Tysabri for multiple sclerosis.

[geoff80] 16/11/2016 17:15

RNS Number : 2693P

IXICO plc

16 November 2016

16(th) November 2016

IXICO plc

("IXICO" or the "Company")

IXICO to receive EUR100k funding to provide digital technologies for collection and analysis of data in a "real world" setting

Further expansion of work on wearable bio-sensors as part of a major EU public-private partnership (ROADMAP)

IXICO, the brain health company, today announces its participation in a new collaborative pan-European research effort under the Innovative Medicines Initiative's (IMI) umbrella focused on addressing the challenges of successfully delivering therapies to people with Alzheimer's disease (AD).

In this collaboration with leading pharmaceutical companies and academics, IXICO is receiving EUR100k of funding to undertake data aggregation and analysis using its digital technology platforms. The platforms will be used to devise clinically meaningful measurements from biosensors worn by patients, and to develop enhanced models of disease progression to help select the most appropriate treatment for an individual patient. Within ROADMAP, IXICO will demonstrate how both approaches can be deployed in real-world settings, leveraging IXICO's existing activities in the Cygnus real world evidence (RWE) study (hxxp://www.ixico.com/news/2016/06/ixico-cygnus-joins-DPUK).

Derek Hill, CEO of IXICO, said: "IXICO is delighted to be joining the ROADMAP consortium. It provides an excellent opportunity for us to advance our capabilities in wearable biosensors and digital disease models, working collaboratively with leading pharmaceutical companies and academics. These are key technologies that are likely to accelerate the approval of and access to beneficial treatments for AD, and we believe they will provide commercial growth opportunities for IXICO."

This project will enhance capabilities currently integrated into IXICO's TrialTracker(TM) and Assessa(R) digital health platforms, which are used by pharmaceutical companies both to support development of new treatments and used alongside marketed drugs. This innovative collaboration brings together 22 leading academic, healthcare and pharmaceutical partners, including Novartis Pharma AG, Eli Lilly and Company Ltd, Biogen, F. Hoffman-La Roche Ltd, Janssen Pharmaceutica NV, GE Healthcare Ltd and AC Immune SA. ROADMAP is also looking to identify which combinations of clinical tests and biomarkers support accurate diagnosis and prognosis of disease in asymptomatic patient populations in Alzheimer's disease.

For further information please contact:


IXICO plc
Derek Hill, Chief Executive Officer Tel: +44 20
Susan Lowther, Chief Financial Officer 3763 7499

Shore Capital (Nomad and Broker) Tel: +44 20
Bidhi Bhoma / Edward Mansfield 7408 4090

FTI Consulting Limited (Investor Tel: +44 20
Relations) 3727 1000
Simon Conway/Mo Noonan/Matthew
Moss


About IXICO

IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health.

More information is available on www.ixico.com

About ROADMAP

ROADMAP aims to provide the foundation for a much-needed integrated data environment and framework for Real World Evidence (RWE) in AD including:

-- The development of consensual key outcome measures across stakeholder groups;
-- Enabling data integration tools for dataset characterisation and outcome classification, data standards, data sourcing, software application repository;

-- Guidelines on the handling and interpretation of RWE data.
In addition, the following priorities have been identified:

-- Outcome measurement;
-- Identifying the best natural history model;
-- Identifying the best pharmacoeconomic modelling strategy;
-- Using short-term data to model long-term effects;
-- Using short-term data to model long-term economic impact;
-- Association between cognition, QoL (quality of life) and function over the AD spectrum;
-- Identifying combination markers for diagnosis in asymptomatic patient population;
-- Identifying combination markers for prognosis.
ROADMAP is mainly sponsored by the European Union's Horizon 2020 research and innovation programme and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative 2 Joint Undertaking.

The ROADMAP programme has budget of EUR7.77M distributed across a total of 22 partners from the private and academic sectors:



* The University of Oxford * London School of Economics and Political Science


* National Institute for Health and Care Excellence * Agentschap College ter Beoordeling van Geneesmiddelen


* Erasmus Universitair Medisch Centrum Rotterdam * IXICO Technologies Ltd


* Universiteit Maastricht * Rijksuniversiteit Groningen


* Synapse Research Management Partners S.L. * Novartis Pharma AG (Project Leader)


* Fundació Institut Universitari per la Recerca a * Eli Lilly and Company Ltd
l'Atenció Primària de Salut Jordi Gol i
Gurina
* Biogen

* Københavns Universitet
* F. Hoffman-La Roche Ltd

* Alzheimer Europe
* Janssen Pharmaceutica NV

* The University of Edinburgh
* GE Healthcare Ltd

* Goeteborgs Universitet
* AC Immune SA

* Aarhus Universitet

About the Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA.

More information can be found at www.imi.europa.eu

Acknowledgement

The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA




Disclaimer

This communication reflects the views of the ROADMAP Consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.

This information is provided by RNS

The company news service from the London Stock Exchange

END

[geoff80] 16/11/2016 17:12

LSE:IXI
OKSearch




Ixico Share News (IXI)
5
Follow IXI
Share Name Share Symbol Market Type Share ISIN Share Description
Ixico LSE:IXI London Ordinary Share GB00BCLY7L40 ORD 1P
Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
+0.50p +2.04% 25.00p 24.00p 26.00p 25.00p 24.50p 24.50p 7,318 10:06:15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 3.1 -1.4 -7.9 - 6.62
Print
Alert
IXICO plc Participation in major EU partnership (ROADMAP)

16/11/2016 7:00am
UK Regulatory (RNS & others)


IXICO plc

16 November 2016

16(th) November 2016

IXICO plc

("IXICO" or the "Company")

IXICO to receive EUR100k funding to provide digital technologies for collection and analysis of data in a "real world" setting

Further expansion of work on wearable bio-sensors as part of a major EU public-private partnership (ROADMAP)

IXICO, the brain health company, today announces its participation in a new collaborative pan-European research effort under the Innovative Medicines Initiative's (IMI) umbrella focused on addressing the challenges of successfully delivering therapies to people with Alzheimer's disease (AD).

In this collaboration with leading pharmaceutical companies and academics, IXICO is receiving EUR100k of funding to undertake data aggregation and analysis using its digital technology platforms. The platforms will be used to devise clinically meaningful measurements from biosensors worn by patients, and to develop enhanced models of disease progression to help select the most appropriate treatment for an individual patient. Within ROADMAP, IXICO will demonstrate how both approaches can be deployed in real-world settings, leveraging IXICO's existing activities in the Cygnus real world evidence (RWE) study (hxxp://www.ixico.com/news/2016/06/ixico-cygnus-joins-DPUK).

Derek Hill, CEO of IXICO, said: "IXICO is delighted to be joining the ROADMAP consortium. It provides an excellent opportunity for us to advance our capabilities in wearable biosensors and digital disease models, working collaboratively with leading pharmaceutical companies and academics. These are key technologies that are likely to accelerate the approval of and access to beneficial treatments for AD, and we believe they will provide commercial growth opportunities for IXICO."

This project will enhance capabilities currently integrated into IXICO's TrialTracker(TM) and Assessa(R) digital health platforms, which are used by pharmaceutical companies both to support development of new treatments and used alongside marketed drugs. This innovative collaboration brings together 22 leading academic, healthcare and pharmaceutical partners, including Novartis Pharma AG, Eli Lilly and Company Ltd, Biogen, F. Hoffman-La Roche Ltd, Janssen Pharmaceutica NV, GE Healthcare Ltd and AC Immune SA. ROADMAP is also looking to identify which combinations of clinical tests and biomarkers support accurate diagnosis and prognosis of disease in asymptomatic patient populations in Alzheimer's disease.

For further information please contact:


IXICO plc
Derek Hill, Chief Executive Officer Tel: +44 20
Susan Lowther, Chief Financial Officer 3763 7499

Shore Capital (Nomad and Broker) Tel: +44 20
Bidhi Bhoma / Edward Mansfield 7408 4090

FTI Consulting Limited (Investor Tel: +44 20
Relations) 3727 1000
Simon Conway/Mo Noonan/Matthew
Moss


About IXICO

IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health.

More information is available on www.ixico.com

About ROADMAP

ROADMAP aims to provide the foundation for a much-needed integrated data environment and framework for Real World Evidence (RWE) in AD including:

-- The development of consensual key outcome measures across stakeholder groups;
-- Enabling data integration tools for dataset characterisation and outcome classification, data standards, data sourcing, software application repository;

-- Guidelines on the handling and interpretation of RWE data.
In addition, the following priorities have been identified:

-- Outcome measurement;
-- Identifying the best natural history model;
-- Identifying the best pharmacoeconomic modelling strategy;
-- Using short-term data to model long-term effects;
-- Using short-term data to model long-term economic impact;
-- Association between cognition, QoL (quality of life) and function over the AD spectrum;
-- Identifying combination markers for diagnosis in asymptomatic patient population;
-- Identifying combination markers for prognosis.
ROADMAP is mainly sponsored by the European Union's Horizon 2020 research and innovation programme and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative 2 Joint Undertaking.

The ROADMAP programme has budget of EUR7.77M distributed across a total of 22 partners from the private and academic sectors:



* The University of Oxford * London School of Economics and Political Science


* National Institute for Health and Care Excellence * Agentschap College ter Beoordeling van Geneesmiddelen


* Erasmus Universitair Medisch Centrum Rotterdam * IXICO Technologies Ltd


* Universiteit Maastricht * Rijksuniversiteit Groningen


* Synapse Research Management Partners S.L. * Novartis Pharma AG (Project Leader)


* Fundació Institut Universitari per la Recerca a * Eli Lilly and Company Ltd
l'Atenció Primària de Salut Jordi Gol i
Gurina
* Biogen

* Københavns Universitet
* F. Hoffman-La Roche Ltd

* Alzheimer Europe
* Janssen Pharmaceutica NV

* The University of Edinburgh
* GE Healthcare Ltd

* Goeteborgs Universitet
* AC Immune SA

* Aarhus Universitet

About the Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA.

More information can be found at www.imi.europa.eu

Acknowledgement

The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020. This

[jondev] 19/10/2016 10:32

Now the CEO is on a nice jolly to Washington DC. Shame the shares are plummeting - it's like phytopharm all over again....

[jpuff] 14/9/2016 17:17

A very depressing share this one!

[jpuff] 26/7/2016 20:22

Very quiet on here. Seems like a good little company with excellent growth prospects too. Anyone else around with a view? Cheers

[jondev] 20/6/2016 15:36

Why is it plummeting like this? Any bad news?

[mrsapeslaptop] 04/4/2016 11:16

nearly there

[mrsapeslaptop] 30/3/2016 17:55

it wants to go above 40p. what will drive it I wonder

[curlly] 22/1/2016 07:26

More good news

[loobrush] 18/1/2016 19:55

Under the radar and going strong-should soon be in profit and could well jump to the analyst 67p level sometime soon,tucked away a few late last year.

[geoff80] 18/1/2016 08:50

Good news.


IXICO plc

18 January 2016

IXICO awarded four contracts worth a combined value of over GBP3.0m

Further cements IXICO's partnerships with leading pharmaceutical and biotechnology companies developing drugs for Alzheimer's disease.

18 January 2016, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, today announces that it has recently been awarded four new contracts with leading pharmaceutical companies and a specialist biotechnology company, with a combined value of over GBP3.0m.

The contracts are for global clinical trials of novel drugs for Alzheimer's disease which span the three major phases of drug development and are expected to run for the next two to four years, subject to the drugs successfully progressing through the clinical trials process. They will utilise IXICO's expertise in the Alzheimer's field and our proprietary TrialTracker(R) and Assessa(R) digital platforms to collect imaging data and quantify changes in disease pathology in subjects enrolled in the study.

The award of these contracts builds on IXICO's expertise in brain health following a long term contract for a Phase II/III global study in neurodegenerative disease and selection as the imaging analysis partner within The European Prevention of Alzheimer's Dementia Initiative (EPAD), announced in 2015.

Professor Derek Hill, Chief Executive Officer of IXICO, commented: "We are very pleased to have been awarded these significant projects. Not only do they validate the value our digital platforms provide, but also highlight the strength of IXICO's relationships with pharmaceutical and biotechnology companies developing drugs for Alzheimer's disease. The revenues from these contracts augment the board's confidence in meeting market expectations."

[fillipe] 30/10/2015 12:16

IXI Being bought a bit this morning and up to almost the full ask of 35p.

Stock still extremely tight here with only 7k showing at each side of the bid/ask. Those 7k on the ask run all the way up to 48p being asked for the last 1000 shrs.

It's almost impossible for IXI not to see a major uptick if even modest concerted buying is seen.

Well worth pinning some down whilst the share price is more than reasonable, imo.

f

[huckle9] 16/10/2015 00:25

#undertheradar

[aishah] 02/9/2015 11:11

Clinical trial contract award raising the bar

IXICO has secured one of its biggest contracts yet, worth $7m over seven years for clinical trial services. The award supports our investment thesis and financial forecasts, reflecting strong growth through the expansion into new indications, new markets and bigger contracts. IXICO is also well placed to capitalise on the burgeoning use of digital technologies in disease management. Using a DCF, we value IXICO at £10.7m or 63p/share.